

Dr Jeff Davies

Barts
Cancer Institute
Queen Mary University of London



Research Interests

My main research interests are allogeneic haematopoietic stem cell transplantation (HSCT), graft-versus-host disease (GvHD)/graft-versus-leukaemia (GvL) effects and adoptive immunotherapy for haematological malignancies.

My research group focuses on:

- Developing novel approaches to improve allogeneic haematopoietic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers and other diseases.
- Investigating the generation of suppressive donor T cells to control specifically the harmful alloresponses that can cause graft-versus-host disease after allogeneic stem cell transplantation

Major Funders

- Medical Research Council
- Bloodwise
- Barts and the London Charity

Contact Details

Email: j.k.davies@qmul.ac.uk



Barts and The London
School of Medicine and Dentistry

www.bci.qmul.ac.uk

Dr Jeff Davies

Barts
Cancer Institute
Queen Mary University of London



Recent Publications

- Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben JG, **Davies JK**. TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. *Blood* 2016. Jul 7;128(1):72-81. PMID: 27103745
- Kotsiou E, Gribben JG, **Davies JK**. Allospecific Tregs expanded after anergization remain suppressive in inflammatory conditions but lack expression of gut-homing molecules. *Molecular Therapy* 2016. Jun;24(6):1126-34. PMID: 27049761
- CM Barbon*, **JK Davies***, A Voskertchian, RH Kelner, L. Brennan, LM Nadler, EC Guinan. CD8+ Suppressor T Cells Contribute to Alloantigen-specific Immune Tolerance After Alloanergization. *American Journal of Transplantation* 2014 14(2):305-18. PMID: 24410845
* Joint first authorship
- **Davies JK**, Gribben JG Blockade of Chemotaxis in graft-versus-host disease. *New England Journal of Medicine* 2012 Oct 25 367(17) 1667 PMID: 23094739